ABSTRACT
The development of oncology drugs is a focus of the pharmaceutical industry. Hundreds of novel therapies are in clinical development. Clinicians have a lot to teach emerging clinical decision support systems. Biomarkers with known and suspected clinical value can be visualized within the context of intact tissue using immunohistochemistry or in situ hybridization. Clinical trials demonstrate a favorable risk-benefit ratio for patients selected with the new diagnostic. Clinical trials are an important source of information, and comprehensive patient profiles can be established in clinical trials to better distinguish between responders and non-responders to the therapy under investigation. A broad diagnostic workup including multiple genomic and phenomic biomarkers could help to improve the understanding of a drug's mechanism of action, its pharmacodynamics, tumor heterogeneity, and mechanisms of therapy evasion. Patient profiling and therapy matching will help to create the future of cancer care. They will bring together the promises of immunotherapy and digital healthcare.
